|
|
Upfront Briefing
FDA pushed LEQEMBI IQLIK’s subcutaneous starting-dose Priority Review PDUFA out to Aug. 24 — a clean ~3-month timeline slip for anyone modeling near-term lifecycle uplift.
On the capital side, Odyssey priced an upsized IPO and concurrent TPG private placement for ~$304M gross proceeds, while Blackstone Life Sciences put $250M behind Anagram’s oral enzyme replacement therapy for pancreatic insufficiency.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,337.1 |
(0.4%) |
+7.2% |
| Nasdaq 100 |
28,563.9 |
(0.1%) |
+13.1% |
| Russell 2000 |
2,839.6 |
(1.6%) |
+14.4% |
| Healthcare (XLV) |
144.7 |
(0.5%) |
+5.6% |
| Biotech (XBI) |
133.7 |
(2.9%) |
+9.6% |
| Nasdaq Biotech (NBI) |
5,902.5 |
(2.2%) |
+3.4% |
| Clinical Trials (BBC) |
44.2 |
(3.9%) |
+14.7% |
|
- Risk-off after Wednesday's record close: S&P 500 (0.4%) and Nasdaq 100 (0.1%) faded as oil rebounded from session lows on Iran-deal uncertainty (Trump flagged the framework was "not certain") and traders booked profits in chips — Micron, Broadcom and Lam Research all sold off after Wednesday's AMD-led semis melt-up.
- Biotech beta hit harder than the tape: XBI (2.9%), NBI (2.2%) and BBC (3.9%) underperformed despite a still-active deal/IPO calendar — when broad markets de-risk, clinical-stage names lose their bid first regardless of supportive single-name catalysts.
- YTD signal still constructive on the small-cap side: XBI +9.6% and BBC +14.7% remain ahead of broader healthcare (XLV +5.6%) — the divergence reflects flow returning to clinical-stage beta through 2026, even as Thursday’s session punished the highest-beta names.
- Market data: U.S. close Thu 07-May-2026.
The Big 3
|
1
|
LEQEMBI IQLIK subQ starting-dose PDUFA slips ~3 months to Aug. 24
|
- FDA extended the Priority Review for Eisai/BioArctic's lecanemab subcutaneous starting dose by three months, moving the PDUFA action date from May 24 to Aug. 24, 2026. The agency classified additional information already submitted as a major amendment, triggering the standard Class 2 extension; FDA has not raised any approvability concerns to date.
- Why it matters: The slip is administrative, not clinical — but it pushes the autoinjector-led patient acquisition narrative for Iqlik into Q4. SubQ maintenance was already approved Aug. 2025; the missing piece is letting patients start on the autoinjector instead of an IV induction, which is the lever for materially expanding community/non-infusion-center prescribing. For Eisai (and indirectly Biogen, who shares ex-US economics), models leaning on a 2H ramp from broader site-of-care access need a one-quarter haircut. No read-through to lecanemab efficacy or safety.
- Source: Eisai PR; BioArctic PR
|
|
2
|
Odyssey prices upsized $279M IPO at top of range; concurrent $25M TPG private placement takes proceeds to ~$304M
|
- Odyssey Therapeutics (ODTX) priced 15.5M shares at $18 — top of the $16–18 marketed range — for ~$279M, plus a 1.39M-share concurrent placement to TPG Life Sciences Innovations at the IPO price for ~$25M, taking expected gross proceeds to ~$304M before fees. 30-day greenshoe of 2.325M shares could push proceeds higher. JPM, TD Cowen and Cantor lead-managed; trades on the Nasdaq from May 8.
- Why it matters: Three signals worth pricing in. (1) Differentiated immunology mid-stage assets clear: lead OD-001 is an oral RIPK2 scaffolding inhibitor that hit Phase 2a proof-of-concept in UC and is advancing to Phase 2b mono and a Phase 2a combo with vedolizumab — an innate-immunity angle differentiated from the TNF/IL-23/JAK lane. (2) Insider and crossover validation is real: TPG sized up at the IPO price after participating in last September's $213M Series D, and Odyssey enters public life with ~$1B in total raised across rounds. (3) Founder pedigree is a tailwind: CEO Gary Glick previously founded Scorpion Therapeutics, which Lilly bought for up to $2.5B in 2025. Read-through: peer Phase 2 immunology names with crossover support look better marked, and the tier of "$300M+ upsized at top" IPOs is now a real 2026 cohort.
- Source: PR More: Reuters; BioPharma Dive
|
3 |
Blackstone Life Sciences invests $250M in Anagram for first non-porcine oral PERT |
- BXLS committed $250M to Anagram Therapeutics to fund development, approval and launch of ANG003 — a recombinant oral enzyme replacement therapy for exocrine pancreatic insufficiency (EPI) in cystic fibrosis, pancreatic cancer and related disorders. Anagram is initiating an international Phase 2 study following positive prior clinical data in CF-EPI. Builds on $30M+ of prior support from the Cystic Fibrosis Foundation.
- Why it matters: The asset has two definable launch levers in a ~$2B US market currently served exclusively by porcine-derived extracts (with recurring global supply shortages). First, ANG003 would be the first non-porcine recombinant entrant — a structural supply-chain de-risk for payors and providers. Second, the dosing profile collapses pill burden from up to 40 capsules/day to roughly one tablet per meal (~3/day), the kind of compliance differentiator that drives switching even in a sleepy category. The structural read-through: BXLS's product-style late-development capital is competitive with classic VC syndicates for assets with definable launch economics and foundation-validated clinical packages — particularly where a therapy can displace a high-burden chronic regimen.
- Source: PR More: Fierce
|
Everything Else That Broke
- FDA reversed course on Atara/Pierre Fabre's twice-rejected Ebvallo (tab-cel) after a constructive Type A meeting agreed a single-arm, historical-control study can support the BLA — the first regulatory signal a week after CBER director Vinay Prasad's exit; ATRA opened up ~37%. Pierre Fabre will resubmit with expanded ALLELE Phase 3 data; ATRA expects another regulatory update in 3Q. — BioSpace
- enGene (ENGN) shares fell sharply after updated LEGEND pivotal cohort data in BCG-unresponsive NMIBC: 54% any-time CR / 43% at 6 months / 25% Kaplan-Meier 12-month CR estimate (median DoR 37.3 weeks). Durability concerns vs. earlier 63% CR datapoint; BLA filing update now H2 2026. — PR; Endpoints
- Entrada (TRDA) reported positive ELEVATE-44-201 Cohort 1 in DMD exon-44 skipping: statistically significant Time-to-Rise velocity improvement at 6 mg/kg, dystrophin production, mild/moderate AEs only; Cohort 2 dosing at 12 mg/kg now underway. Cash to Q3 2027. — PR
- CytomX Q1 results spotlight Phase 1 EpCAM PROBODY ADC dose-expansion update in colorectal cancer. — PR
- Astellas highlights early stem cell-derived eye therapy data. — Endpoints
- BioCentury: Mounjaro overtakes Keytruda for the first time. — BioCentury
- BioCentury: Two mechanisms vie in hypoxic ischemic encephalopathy. — BioCentury
- IN8bio reports Q1 2026 results and business highlights. — PR
- Genelux Q1 results; Phase 3 ovarian topline expected 2H26. — PR
- Cognition Q1 results; FDA Psychiatry meeting planned May 2026. — PR
- Jade Biosciences reports Q1 2026 results and corporate update. — PR
- NextCure reports Q1 2026 financial results and business update. — PR
- 4D Molecular Therapeutics Q1 results include upcoming milestones. — PR
- PacBio announces Q1 2026 financial results. — PR
- Nephros reports financial results for quarter ended March 31. — PR
- Chance Pharma says NMPA accepted NDA for respiratory drug CXG87. — PR
- Opus Genetics presents ARVO 2026 data in inherited retinal disease. — PR
- Corline Biomedical AB publishes interim report for Jan–Mar 2026. — PR
- Persistent earns Databricks Brickbuilder specialization for life sciences. — PR
Deal Flow
M&A / BD&L
- No notable new M&A / BD&L since yesterday.
VC / Private Financings
- Anagram Therapeutics secured $250M from Blackstone Life Sciences (sole investor) to develop, seek approval for and launch ANG003, a novel oral recombinant enzyme replacement therapy for exocrine pancreatic insufficiency. Builds on >$30M of prior support from the Cystic Fibrosis Foundation. — PR
- Banyan BioInnovations launched with more than $100M in initial commitments from life-science investors and a strategic ICON collaboration, using an asset-centric model to build NewCos around clinical-stage drug assets. — PR; Fierce
IPOs / Follow-Ons
- Odyssey Therapeutics priced an upsized IPO and concurrent TPG Life Sciences Innovations private placement for expected gross proceeds of ~$304M. — PR
- Cytokinetics priced an upsized $700M public offering of 9.86M shares at $71/share, with a 30-day underwriter option for a further 1.48M shares. — PR
- Mobia Medical priced its IPO at $15/share, raising ~$150M gross proceeds to fund its commercial-stage stroke-recovery neuromodulation platform. — PR
|
|
That’s it for today — may your PDUFAs stay put, your IPO windows stay open, and your private placements price at the offer. See you next edition. BioBucks Team
|
|
|
